The company specializes in developing drugs to target disease-modifying therapeutics for the central nervous system and neuron-reviving therapeutics which enable an intrinsic ability of CNS neurons, enabling the healthcare industry to resist neurodegeneration, restore excitation, and regenerate neurons. Axonis is developing a pipeline of neuron-reviving therapeutics to tackle adult-onset central nervous system disorders, which are an urgent, unmet, global and growing burden.